[PSA and hormone-refractory period in prostatic cancer].
Study of the characteristics of the hormone-refractory period in 32 patients with disseminated prostate cancer who had achieved a complete response to total androgen suppression, appreciating in all of them a subclinical or asymptomatic stage and a clinical or symptomatic one. The subclinical stage was characterized by raised PSA levels and ranged between 3-35 months; at 12 months 59% of patients had advanced to the symptomatic stage, while at 24 months this percentage is 84%. The clinical stage extends from appearance of symptoms to the patient's death, ranging from 3 to 32 months; at 12 months 41% has died; and 91% at 2 years.
Ojea Calvo
A
A
Servicio de Urología, Hospital Xeral de Vigo, Pontevedra.
Verez
M
M
Alonso
A
A
Rodríguez
B
B
Domínguez
F
F
Benavente
J
J
Barros
J M
JM
Nogueira March
J L
JL
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen
PSA y periodo hormonorrefractario del cáncer de próstata.